Share Name Share Symbol Market Type Share ISIN Share Description
Proactis Holdings Plc LSE:PHD London Ordinary Share GB00B13GSS58 ORD 10P
  Price Change % Change Share Price Shares Traded Last Trade
  -2.35 -5.45% 40.75 476,296 16:26:37
Bid Price Offer Price High Price Low Price Open Price
40.50 41.00 43.10 39.10 43.10
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Software & Computer Services 49.57 -19.34 -19.90 39
Last Trade Time Trade Type Trade Size Trade Price Currency
17:20:09 O 2,850 40.75 GBX

Proactis (PHD) Latest News

More Proactis News
Proactis Investors    Proactis Takeover Rumours

Proactis (PHD) Discussions and Chat

Proactis Forums and Chat

Date Time Title Posts
07/3/202120:39PROACTIS Holdings PLC11,367
11/5/201918:08Rodneey Potts2
09/4/201909:27Proactis (PHD) HSBC UK to bring new technology to the market3
03/11/200817:39Proactis, Major product upgrade3

Add a New Thread

Proactis (PHD) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Proactis trades in real-time

Proactis (PHD) Top Chat Posts

Proactis Daily Update: Proactis Holdings Plc is listed in the Software & Computer Services sector of the London Stock Exchange with ticker PHD. The last closing price for Proactis was 43.10p.
Proactis Holdings Plc has a 4 week average price of 39.10p and a 12 week average price of 39.10p.
The 1 year high share price is 51.50p while the 1 year low share price is currently 14p.
There are currently 95,532,628 shares in issue and the average daily traded volume is 82,237 shares. The market capitalisation of Proactis Holdings Plc is £38,929,545.91.
cureboy: That Vox Markets fella doesn't pause for breath does he. Whereas the share price here moves slower than a turtle.
jonstrawberry: Dear Tim, You have been CEO of Proactis for several years now, and prior to that the company's CFO for over a decade. Therefore, you are undeniably responsible for the the company's strategy, execution of that strategy and, ultimately, its performance. And that performance has been dreadful. The company's M&A strategy has resulted in a business crippled with debt, unable to extract the value of its acquisitions, and encumbered by the (substantial parts) of the aggregated cost bases of each acquired business. The preference to focus on the Board on an M&A (roll-up) strategy was entirely your idea, which you promoted to Rod Jones, Alan Aubrey and Rodney Potts and began in 2006. In many cases, insufficient due diligence was performed on the acquisitions and it is also true that the Proactis leadership team, in several cases, did not understand the company, product or market they were buying. I met Rod Jones once and discussed this M&A strategy. He said to me, and I will always remember this, "two dogs shagging is still only two dogs shagging". Well, there are a few more than two dogs in the Proactis story, but this still holds very true today. He further explained to me that organic growth through sales was simply too difficult and it was easier to "do an Infor". He credited you as the brains behind this strategy; something you later boasted to me as well. Meanwhile, the company's market execution has been woeful with organic sales seemingly flat over the last decade plus. At a time when the SAAS spend management market has quite literally exploded, with many new players entering the market and immediately out-positioning, out-selling and ultimately out-growing Proactis in a short space of time. How can it be that a company that did not exist when Proactis topped the Gartner product ratings in 2009, Coupa, is now valued at $28bn, purely by pursuing the market that Proactis once promised to "own", while Proactis is still a sub £50m market cap firm with little prospect of ever breaking through? And GEP, a privately owned firm with zero outside investment, has grown into multi-hundred million dollar sales organisation in the last 7 years, while Proactis has been playing its pointless M&A games. And Ivalua is securing public sector contracts which (in at least one example) eclipse Proactis' entire annual revenue in one deal. These failures are laid bare for all to see in the company's results and reflected fairly in the share price. Many of us shareholders still believe this market has ample growth left in it. And that the Proactis product is still fundamentally a sound one. With the company's very best intentions at heart, and the above points taken into consideration, I implore you to stand down and for the Board to appoint a new leadership team capable of executing on the promise of Proactis. You have had more than a fair shot, plenty of backing from the Board and investors to make it work, and you have sadly failed. Move on, sir, and give this company a chance to re-build. Yours, A concerned (very long term) investor
cureboy: Share price is very easily manipulated by the larger shareholders here.
cureboy: Regular pattern of rounded trades just above the bid price at 47.20p could be more accumulation as having no negative affect on share price.
cureboy: Not sure on that Billy. DBAY have consistently bought on the bid price. Millions bought at 35p when the share price was 36/37p. Evidenced by RNS notifications. This is now above the bid. It looks like they’re buying more as the share price hasn’t moved. Don’t know how they do it but quite frustrating to the rest of us.
cureboy: Tim answered my question on FSP - offers were from PE companies wanting to break things up and/or deemed not suitable. A lot of interest at start of FSP, two companies remained interested at the end of FSP. He did say that the offers were at a time when share price was low and wasn’t at a level suitable for shareholder value - however no comment on the fact there’s not much progress on the share price front since! However all in all, a positive presentation. They believe they’re well placed to exploit US, German and French markets.
cureboy: Depends on what kind of spin you wanna put on it. A seven year contract win in a strategic location is important as it will open up doors. Anthony Persse may have simply left to fulfil a CEO ambition, we will never know. BePayd was relatively low cost to set up so doesn’t need to deliver mega revenues to pay for itself as a bolt on. I don’t think anyone’s pinning their hopes on it. They shouldn’t be. Fy2020 results should be in line with expectations and relatively boring. There’ll be a COVID lull but same for most. Will only move the share price one or two pence either way anyway. DBAY are in control of the share price.
cureboy: With DBAY accumulating and Lombard sat at 29% there’s a floor in the share price where we are now. Also happens to be about the average of a few board members. Not many sellers left now that the likes of Artemis and L&G sold out. DBAY switching stock between various entities which is why their accumulation hasn’t sent the share price up. They’re very adept. Once DBAY have a place on the board they’ll try to push through a deal.
p1nkfish: coldspring, Please learn to read. I have no idea if he will die but at 76 the probability is higher than at 56 and there is now a major vulnerabillity. PHD is now very vulnerable to an opportune low ball bid and knowing their luck it could happen. If you bothered to research you would also get the vibe from other SaaS companies wrt current cashflow. Very important in the PHD case. As for the future, DBAY bought the company referenced below and if you USE YOUR BRAIN you might understand the parallels to PHD. Also, if you are so f'in Smart, please tell us the role Advent MIGHT PLAY if there is a bid - go on - elighten us all. 1) Expanded too fast at the expense of profitability. 2) Not enough atention to cash. 3) Great optimism about the group’s prospects — may be excessive. 4) Cashflow and timing poor, in vs out. 5) Borrowing was expected to fall but rose instead. +++ I hold here but its now on a knifes edge imho. Best case is 2 interested parties looking to take it private. What I thought wouild be an 18-36 month share price recovery will either end in a low ball sale or take 5 yrs imho. I don't think thats bipolar, it's posting as new info becomes available.
cureboy: DBAY are firmly in control of the share price here though having accumulated 13% whilst holding the share price down.
Proactis share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210307 22:10:56